Raptiva® Withdrawn From Market for High Risk of Fatal Brain Disease We are investigating cases in which Raptiva® users have experienced neurological changes including unusual weakness, loss of coordination and changes in vision. On April 8, 2009, the drug manufacturer Genentech announced a phased withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. market. Since October 2008, Raptiva® has been associated with a higher risk for progressive multifocal leukoencephalopathy (PML), a rare, and often fatal neurologic viral disease that affects the central nervous system. The associations between Raptiva® and PML are generally associated with individuals with weakened immune systems. Symptoms of PML may include: -Unusual weakness -Loss of coordination -Changes in vision -Difficulty speaking -Personality changes -Other neurological changes -Death There are no known effective therapeutic options for PML, and no known screening tests that can reliably predict PML. The PML infection often leads to an irreversible decline in neurologic and brain function and death. People who live with PML are severely disabled. The product withdrawal plans to remove Raptiva® by June 8, 2009. According to the FDA, prescribers should not initiate new Raptiva® treatment.. The phased withdrawal is designed to allow patients time to find other effective treatments for psoriasis so as to avoid severe worsening of the condition or hospitalization. History of Raptiva® Raptiva® was... Vew Complete Article NESTLE® TOLL HOUSE® Refrigerated Cookie Dough Recalled - FDA Issues Warning After 65 people became hospitalized after eating refrigerated cookie dough, the NESTLE company has issued a voluntary... FDA Alerts Consumers Concering Zicam® Zicam® Jon L. Gelman LLC is investigating cases involving individuals who have suffered the loss of taste and smell... Vaccinating Workers’ Compensation Against Flu Claims The spread of influenza A has now reached pandemic proportions. The focus has now been directed to creating a vaccine to... Garfield Chromium Ground Water Contamination 1-800-868-0020 We are currently investigating potential claims arising out of the Chromium Ground Water Contamination in Garfield NJ. Its... Hydroxycut® Products Withdrawn From Market After FDA Consumer Advisory Warning Jon L. Gelman is investigating potential cases involving users of Hydroxycut® products who have experienced health problems

Home  |  Firm Information  |  Practice Areas  |  Reading Room  |  Careers  |  Gelman Foundation  |  Join our email list  |  Contact Us  |  Disclaimer  |  Privacy Policy  |  Directions © 2009 Jon L. Gelman LLC. All rights reserved.